A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).

Inclusion criteria:

• Age ≥18 years.
• Written informed consent prior to any study-related procedure
• Willing and able to comply with protocol-specified procedures and scheduled evaluations
• Pathological diagnosis of nasopharyngeal carcinoma (NPC)
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1or 2
• Absolute neutrophil count (ANC) > 0.5 x 109/L
• Haemoglobin > 80 g/L
• Platelet count ≥ 50 x 109/L
• Total bilirubin ≤ 2 x the upper limit of normal (ULN)
• Alanine transaminase (ALT) ≤ 5 x ULN
• Serum creatinine ≤ 2 x ULN

Exclusion criteria:

• History or clinical evidence of neoplastic central nervous system (CNS) involvement. Note: Irradiated brain metastases that have been stable for > 1 month and do not require systemic glucocorticoid administration are allowed
• Major surgery within 4 weeks of ARGX-110 first dose administration
• Unresolved grade 3 or 4 toxicity from prior therapy (except mucositis from local radiation therapy).
• Active, untreated viral, bacterial, or systemic fungal infection
• Childbearing potential unless using an adequate measure of contraception
• Pregnancy or lactation. History of hypersensitivity to recombinant proteins
• Any clinical finding, including psychiatric and behavioural problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study